Abstract
Objective: To describe the frequency, intensity and duration of urological chronic pelvic pain syndrome symptom exacerbations (‘flares’), as well as risk factors for these features, in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Epidemiology and Phenotyping longitudinal study. Participants and Methods: Current flare status (‘urological or pelvic pain symptoms that are much worse than usual’) was ascertained at each bi-weekly assessment. Flare characteristics, including start date, and current intensity of pelvic pain, urgency and frequency (scales of 0–10), were assessed for participants’ first three flares and at three randomly selected times when they did not report a flare. Generalized linear and mixed effects models were used to investigate flare risk factors. Results: Of the 385 eligible participants, 24.2% reported no flares, 22.9% reported one flare, 28.3% reported 2–3 flares, and 24.6% reported ≥4 flares, up to a maximum of 18 during the 11-month follow-up (median incidence rate = 0.13/bi-weekly assessment, range = 0.00–1.00). Pelvic pain (mean = 2.63-point increase) and urological symptoms (mean = 1.72) were both significantly worse during most flares (60.6%), with considerable within-participant variability (26.2–37.8%). Flare duration varied from 1 to 150 days (94.3% within-participant variability). In adjusted analyses, flares were more common, symptomatic, and/or longer-lasting in women and in those with worse non-flare symptoms, bladder hypersensitivity, and chronic overlapping pain conditions. Conclusion: In this foundational flare study, we found that pelvic pain and urological symptom flares were common, but variable in frequency and manifestation. We also identified subgroups of participants with more frequent, symptomatic, and/or longer-lasting flares for targeted flare management/prevention and further study.
| Original language | English (US) |
|---|---|
| Journal | BJU International |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- epidemiology
- interstitial cystitis
- prostatitis
- symptom flare-up
ASJC Scopus subject areas
- Urology
Cite this
}
A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. / Sutcliffe, Siobhan; Gallop, Robert; Henry Lai, Hing Hung; Andriole, Gerald L.; Bradley, Catherine S.; Chelimsky, Gisela; Chelimsky, Thomas; Quentin Clemens, James; Colditz, Graham A.; Erickson, Bradley; Griffith, James W; Kim, Jayoung; Krieger, John N.; Labus, Jennifer; Naliboff, Bruce D.; Rodriguez, Larissa V.; Sutherland, Suzette E.; Taple, Bayley J.; Landis, John Richard.
In: BJU International, 01.01.2019.Research output: Contribution to journal › Article
TY - JOUR
T1 - A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network
AU - Sutcliffe, Siobhan
AU - Gallop, Robert
AU - Henry Lai, Hing Hung
AU - Andriole, Gerald L.
AU - Bradley, Catherine S.
AU - Chelimsky, Gisela
AU - Chelimsky, Thomas
AU - Quentin Clemens, James
AU - Colditz, Graham A.
AU - Erickson, Bradley
AU - Griffith, James W
AU - Kim, Jayoung
AU - Krieger, John N.
AU - Labus, Jennifer
AU - Naliboff, Bruce D.
AU - Rodriguez, Larissa V.
AU - Sutherland, Suzette E.
AU - Taple, Bayley J.
AU - Landis, John Richard
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objective: To describe the frequency, intensity and duration of urological chronic pelvic pain syndrome symptom exacerbations (‘flares’), as well as risk factors for these features, in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Epidemiology and Phenotyping longitudinal study. Participants and Methods: Current flare status (‘urological or pelvic pain symptoms that are much worse than usual’) was ascertained at each bi-weekly assessment. Flare characteristics, including start date, and current intensity of pelvic pain, urgency and frequency (scales of 0–10), were assessed for participants’ first three flares and at three randomly selected times when they did not report a flare. Generalized linear and mixed effects models were used to investigate flare risk factors. Results: Of the 385 eligible participants, 24.2% reported no flares, 22.9% reported one flare, 28.3% reported 2–3 flares, and 24.6% reported ≥4 flares, up to a maximum of 18 during the 11-month follow-up (median incidence rate = 0.13/bi-weekly assessment, range = 0.00–1.00). Pelvic pain (mean = 2.63-point increase) and urological symptoms (mean = 1.72) were both significantly worse during most flares (60.6%), with considerable within-participant variability (26.2–37.8%). Flare duration varied from 1 to 150 days (94.3% within-participant variability). In adjusted analyses, flares were more common, symptomatic, and/or longer-lasting in women and in those with worse non-flare symptoms, bladder hypersensitivity, and chronic overlapping pain conditions. Conclusion: In this foundational flare study, we found that pelvic pain and urological symptom flares were common, but variable in frequency and manifestation. We also identified subgroups of participants with more frequent, symptomatic, and/or longer-lasting flares for targeted flare management/prevention and further study.
AB - Objective: To describe the frequency, intensity and duration of urological chronic pelvic pain syndrome symptom exacerbations (‘flares’), as well as risk factors for these features, in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Epidemiology and Phenotyping longitudinal study. Participants and Methods: Current flare status (‘urological or pelvic pain symptoms that are much worse than usual’) was ascertained at each bi-weekly assessment. Flare characteristics, including start date, and current intensity of pelvic pain, urgency and frequency (scales of 0–10), were assessed for participants’ first three flares and at three randomly selected times when they did not report a flare. Generalized linear and mixed effects models were used to investigate flare risk factors. Results: Of the 385 eligible participants, 24.2% reported no flares, 22.9% reported one flare, 28.3% reported 2–3 flares, and 24.6% reported ≥4 flares, up to a maximum of 18 during the 11-month follow-up (median incidence rate = 0.13/bi-weekly assessment, range = 0.00–1.00). Pelvic pain (mean = 2.63-point increase) and urological symptoms (mean = 1.72) were both significantly worse during most flares (60.6%), with considerable within-participant variability (26.2–37.8%). Flare duration varied from 1 to 150 days (94.3% within-participant variability). In adjusted analyses, flares were more common, symptomatic, and/or longer-lasting in women and in those with worse non-flare symptoms, bladder hypersensitivity, and chronic overlapping pain conditions. Conclusion: In this foundational flare study, we found that pelvic pain and urological symptom flares were common, but variable in frequency and manifestation. We also identified subgroups of participants with more frequent, symptomatic, and/or longer-lasting flares for targeted flare management/prevention and further study.
KW - epidemiology
KW - interstitial cystitis
KW - prostatitis
KW - symptom flare-up
UR - http://www.scopus.com/inward/record.url?scp=85066501549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066501549&partnerID=8YFLogxK
U2 - 10.1111/bju.14783
DO - 10.1111/bju.14783
M3 - Article
JO - BJU International
JF - BJU International
SN - 1464-4096
ER -